GT200600275A - Formulacion de liberacion prolongada de principios activos de medicamentos - Google Patents

Formulacion de liberacion prolongada de principios activos de medicamentos

Info

Publication number
GT200600275A
GT200600275A GT200600275A GT200600275A GT200600275A GT 200600275 A GT200600275 A GT 200600275A GT 200600275 A GT200600275 A GT 200600275A GT 200600275 A GT200600275 A GT 200600275A GT 200600275 A GT200600275 A GT 200600275A
Authority
GT
Guatemala
Prior art keywords
formulation
prolonged release
medicines
active principles
matricial
Prior art date
Application number
GT200600275A
Other languages
English (en)
Inventor
Gerard Alaux
Frederic Andre
Gareth Lewis
Veronique Serre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600275A publication Critical patent/GT200600275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A FORMULACIÓN DE LIBERACIÓN PROLONGADA, UTILIZABLE CON UN PRINCIPIO ACTIVO QUE PRESENTA UNA SOLUBILIDAD DEPENDIENTE DEL PH, QUE COMPRENDE UN EXCIPIENTE MATRICIAL A BASE DE POLÍMERO HIDRÓFILO, EXCIPIENTE MATRICIAL QUE CONTIENE UNA DOSIS DETERMINADA DEL PRINCIPIO ACTIVO, CARACTERIZADA PORQUE COMPRENDE UNO O VARIOS AGENTES ACIDIFICANTES EN FORMA DE UNA SAL ÁCIDA DE UN ÁCIDO ORGÁNICO.
GT200600275A 2005-06-28 2006-06-27 Formulacion de liberacion prolongada de principios activos de medicamentos GT200600275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0506539A FR2887455B1 (fr) 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments

Publications (1)

Publication Number Publication Date
GT200600275A true GT200600275A (es) 2007-03-29

Family

ID=35708770

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600275A GT200600275A (es) 2005-06-28 2006-06-27 Formulacion de liberacion prolongada de principios activos de medicamentos

Country Status (31)

Country Link
US (1) US20080089936A1 (es)
EP (1) EP1904037A1 (es)
JP (1) JP2008546830A (es)
KR (1) KR101387839B1 (es)
CN (1) CN101217943B (es)
AR (1) AR057410A1 (es)
AU (1) AU2006264856B2 (es)
BR (1) BRPI0612990A2 (es)
CA (1) CA2611125A1 (es)
CR (1) CR9567A (es)
DO (1) DOP2006000144A (es)
EA (1) EA013745B1 (es)
EC (1) ECSP078010A (es)
FR (1) FR2887455B1 (es)
GT (1) GT200600275A (es)
HK (1) HK1122731A1 (es)
HN (1) HN2006023741A (es)
IL (1) IL187901A0 (es)
MA (1) MA29560B1 (es)
MX (1) MX2007016238A (es)
MY (1) MY150069A (es)
NO (1) NO20080420L (es)
NZ (1) NZ564069A (es)
PA (1) PA8682701A1 (es)
PE (1) PE20070098A1 (es)
TN (1) TNSN07438A1 (es)
TW (1) TWI446934B (es)
UA (1) UA91553C2 (es)
UY (1) UY29637A1 (es)
WO (1) WO2007003746A1 (es)
ZA (1) ZA200711035B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
EA201490626A1 (ru) * 2011-09-14 2014-08-29 Поузен Инк. Поэтапное дозирование клопидогрела
IT201700011337A1 (it) * 2017-02-02 2018-08-02 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato per la somministrazione di magnesio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
EP0621777B1 (de) * 1992-01-17 1996-09-11 ALFATEC-PHARMA GmbH Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
WO2000040205A2 (en) * 1999-01-05 2000-07-13 Copley Pharmaceutical Inc. Sustained release formulation with reduced moisture sensitivity
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
AU2004287485A1 (en) * 2003-11-05 2005-05-19 Santarus, Inc. Combination of proton pump inhibitor and sleep aid

Also Published As

Publication number Publication date
NO20080420L (no) 2008-01-22
TWI446934B (zh) 2014-08-01
EA013745B1 (ru) 2010-06-30
CN101217943B (zh) 2012-05-23
JP2008546830A (ja) 2008-12-25
AU2006264856B2 (en) 2011-09-15
FR2887455A1 (fr) 2006-12-29
US20080089936A1 (en) 2008-04-17
KR20080019023A (ko) 2008-02-29
UA91553C2 (ru) 2010-08-10
TW200727921A (en) 2007-08-01
HK1122731A1 (en) 2009-05-29
NZ564069A (en) 2012-04-27
EA200800150A1 (ru) 2008-04-28
BRPI0612990A2 (pt) 2011-04-19
MY150069A (en) 2013-11-29
MX2007016238A (es) 2008-03-06
FR2887455B1 (fr) 2007-08-10
CR9567A (es) 2008-02-20
WO2007003746A1 (fr) 2007-01-11
KR101387839B1 (ko) 2014-04-22
CN101217943A (zh) 2008-07-09
PE20070098A1 (es) 2007-03-01
HN2006023741A (es) 2011-05-31
MA29560B1 (fr) 2008-06-02
TNSN07438A1 (en) 2009-03-17
EP1904037A1 (fr) 2008-04-02
ECSP078010A (es) 2008-01-23
PA8682701A1 (es) 2007-01-17
IL187901A0 (en) 2008-03-20
CA2611125A1 (fr) 2007-01-11
DOP2006000144A (es) 2007-02-28
ZA200711035B (en) 2009-09-30
AU2006264856A1 (en) 2007-01-11
UY29637A1 (es) 2007-01-31
AR057410A1 (es) 2007-12-05

Similar Documents

Publication Publication Date Title
CY1120389T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
CO6160335A2 (es) Vacuna
GT200500246A (es) Combinacion de compuestos organicos
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
ECSP099608A (es) Preparacion solida que comprende alogliptina y pioglitazona
AR081983A1 (es) Articulo de dosis unitaria soluble que comprende un polimero cationico
AR067309A1 (es) Formulaciones farmaceuticas que contienen derivados de acido lipoico
CR20110110A (es) Composicion farmaceutica
ES2422267T3 (es) Disoluciones desinfectantes concentradas de peróxido de hidrógeno
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
AR098168A1 (es) Formulación estable de insulina glulisina
AR059357A1 (es) Formulaciones farmaceuticas
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
ECSP11011001A (es) Composición farmacéutica sólida
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
BRPI0909211B8 (pt) formulação oral em forma de comprimido de compostos de tetraciclina
GT200600275A (es) Formulacion de liberacion prolongada de principios activos de medicamentos
AR054729A1 (es) Sistema de administracion
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
EA201990093A1 (ru) Двухкомпонентная композиция
AR083380A1 (es) Mecanismo de establecimiento de dosis y metodo para utilizar el mismo
CL2010000124A1 (es) Composición antimicrobiana que comprende una formulación acuosa de una sal de polímero-amonio que contiene uno o mas polímeros y una o más sales en una relación molar de cloro con respecto al ion amonio de 1:10 a 10:1 y un álcali; y método para inhibir el crecimiento de los microorganismos en un sistema acuoso.